Related Experiment Video
Updated: Apr 28, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Advances in Antiviral Drug Development Targeting Enteroviruses: From Viral Proteins to Host Factors
Jiaying Lu1, Congyi Li1, Wenzhe Cui1
1Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Virology and AIDS Research, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun 130021, China.
Abstract:
Enteroviruses represent important human pathogens, posing a substantial disease burden, particularly in children under 5 years of age. Enteroviruses are the primary causative agents of hand-foot-and-mouth disease (HFMD) and are strongly associated with acute flaccid myelitis (AFM), with severe cases potentially resulting in significant neurological complications. Inactivated vaccines against EV-A71 based on the C4 genotype are currently available. However, there are no licensed direct antiviral agents for severe cases. By focusing on viral proteins and host factors, researchers have made great strides in the creation of antiviral medications that target enteroviruses. However, several viral candidates failed to progress in clinical development due to limited efficacy or side effects. This review discusses key findings in enterovirus antiviral research, analyzes the advantages and limitations of each drug target, and highlights knowledge gaps that need to be addressed to advance further development in this field.
Insights
Enteroviruses cause significant disease in children, including hand-foot-and-mouth disease and acute flaccid myelitis. This review explores antiviral research for enteroviruses, highlighting challenges and future directions for drug development.
Area of Science:
- Virology
- Infectious Diseases
- Drug Discovery
Background:
- Enteroviruses are significant human pathogens, particularly affecting children under five.
- They are linked to hand-foot-and-mouth disease (HFMD) and acute flaccid myelitis (AFM), with potential for severe neurological complications.
- While some EV-A71 vaccines exist, direct antiviral treatments for severe enterovirus infections are lacking.
Purpose of the Study:
- To review key findings in enterovirus antiviral research.
- To analyze the advantages and limitations of various drug targets.
- To identify knowledge gaps for advancing antiviral development.
Main Methods:
- Literature review of enterovirus antiviral research.
- Analysis of viral protein and host factor targets.
- Evaluation of drug candidate efficacy and safety profiles.
Main Results:
- Several antiviral strategies targeting viral proteins and host factors have shown promise.
- Challenges include limited efficacy and side effects of current drug candidates.
- Existing vaccines are genotype-specific and do not offer broad protection.
Conclusions:
- Further research is needed to develop effective direct antiviral agents for enteroviruses.
- Addressing identified knowledge gaps is crucial for successful drug development.
- A comprehensive understanding of viral mechanisms and host interactions is essential.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Subviral Agents
Retroviruses
Viruses with RNA Genomes

